Clinical Trials in Renal Cell Carcinoma
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.12/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 11, 2018 Category: Urology & Nephrology Source Type: news

An overview of renal cell carcinoma
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.12/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 10, 2018 Category: Urology & Nephrology Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

miR ‑122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Navigating Systemic Therapy in Advanced Thyroid Carcinoma Navigating Systemic Therapy in Advanced Thyroid Carcinoma
Find out more about the available treatment options for advanced cases of thyroid cancer.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Metformin and Risk of HCC in Patients With T2DM Metformin and Risk of HCC in Patients With T2DM
Is metformin use associated with a reduced risk of hepatocellular carcinoma in patients with type 2 diabetes mellitus?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news

How Useful Are Immune Checkpoint Markers in Squamous Cell Carcinoma?
A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 29, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Monoclonal Gammopathy in Prostate Carcinoma Monoclonal Gammopathy in Prostate Carcinoma
This case highlights the possibility of monoclonal gammopathy associated with a solid tumor, without evidence of bone marrow plasmacytosis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Skin cancer rates far higher than previously thought, according to new national database
(Queen Mary University of London) Data from a newly established UK skin cancer database, the largest of its kind in the world, has revealed that there are over 45,000 cutaneous squamous cell carcinomas every year in England, 350 percent more than previous estimates suggested. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 28, 2018 Category: International Medicine & Public Health Source Type: news

Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
An analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney.11/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally.11/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 20, 2018 Category: Urology & Nephrology Source Type: news

New dual-action cancer-killing virus
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. (Source: Medical Research Council General News)
Source: Medical Research Council General News - November 19, 2018 Category: Research Source Type: news

New dual-action cancer-killing virus
(Medical Research Council) Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumors -- healthy cells that are tricked into protecting the cancer from the immune system and supplying it with growth factors and nutrients -- have been specifically targeted in this way. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 18, 2018 Category: International Medicine & Public Health Source Type: news

Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System
In this article, we review the role of temozolomide in the management of patients with primary brain tumors, brain metastases, leptomeningeal carcinomatosis, and other selected CNS cancers. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Karisa C. Schreck, MD, PhD, Stuart A. Grossman, MD Source Type: news

What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

In Older Hep B Patients, Carcinoma Surveillance Is Advised In Older Hep B Patients, Carcinoma Surveillance Is Advised
Patients older than 50 years should still be screened for hepatocellular carcinoma after the 5 years of therapy for chronic hepatitis B, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Liver Disease Risk Factors in Patients Treated for Alcohol and Drug Dependence
Conclusion As this was only a pilot study, further data collection involving a larger, representative sample of clients should be undertaken to explore these results further. References Bennett, H. et al., 2015. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. PLoS ONE, 10(5), p.e0125846. Edeghere, O. et al., 2015. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection. Public Health, 129(5), pp.509–5...
Source: Alcohol Research UK - November 15, 2018 Category: Addiction Authors: admin Tags: Alcohol Insights Source Type: news

Metastasis in Patients With Hepatocellular Carcinoma Metastasis in Patients With Hepatocellular Carcinoma
This authors investigated the prevalence, associated factors, and prognostic impact of metastasis in hepatocellular carcinoma, proposing a modified BCLC system based on metastasis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Trials Presented at ESMO 2018
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Is First-Line Avelumab Effective for Metastatic Merkel Cell Carcinoma?
Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving  avelumab monotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
(Kanazawa University) A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells. Their research sheds light on a novel therapeutic target for treating hepatocellular carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
(eLife) Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Localized Ureteral Amyloidosis Mimicking Urothelial Carcinoma Localized Ureteral Amyloidosis Mimicking Urothelial Carcinoma
How was the unusual origin of this patient's left-sided flank pain determined?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Systemic Therapy Options for Renal Cell Carcinoma
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
KENILWORTH, N.J.--(BUSINESS WIRE) November 9, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2018 Category: Drugs & Pharmacology Source Type: news

Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.11/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 8, 2018 Category: Urology & Nephrology Source Type: news

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy
Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC).11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive assessment gene signatures for clear cell renal cell carcinoma prognosis
There are many prognostic gene signature models in clear cell renal cell carcinoma (ccRCC). However, different results from various methods and samples are hard to contribute to clinical practice. It is necessary to develop a robust gene signature for improving clinical practice in ccRCC. A method was proposed to integrate least absolute shrinkage and selection operator and multiple Cox regression to obtain mRNA and microRNA signature from the cancer genomic atlas database for predicting prognosis of ccRCC.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib Improves PFS in Highly Refractory RCC
The VEGF inhibitor tivozanib (Fotivda) reduced the risk of disease progression or death by 26% compared with sorafenib (Nexavar) in patients with highly refractory advanced or metastatic renal cell carcinoma (RCC), according to topline findings from the phase III TIVO-3 trial.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Tivozanib extends PFS in advanced renal cell carcinoma
Tivozanib extended PFS compared with sorafenib among patients with highly refractory advanced or metastatic renal cell carcinoma, according to randomized phase 3 study results released by the agent ’s manufacturer.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear cell renal cell carcinoma (RCC) that progressed on first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI). The role of cabozantinib has not been established in non-clear cell renal cell carcinoma (nccRCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan
Sunitinib has been shown to offer clinical benefits during the treatment of advanced renal cell carcinoma. However, molecular targeting drugs are expensive and can have a significant impact on medical expenses.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Clinical Utility of Chromosome Genomic Array Testing for Unclassified and Advanced-Stage Renal Cell Carcinomas
Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost.11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company ’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC).11/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 6, 2018 Category: Urology & Nephrology Source Type: news

Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
TAIPEI, Taiwan and SAN DIEGO, Nov. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Senhwa Biosciences Inc. (TPEx: 6492) announced today that FDA has approved its IND application for basal cell carcinoma (BCC). To accelerate the development of this ne... Biopharmaceuticals, Oncology, FDA Senhwa Biosciences, Silmitasertib, basal cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Early Development of De Novo HCC After DAA Therapy Early Development of De Novo HCC After DAA Therapy
The results of this study indicate that chronic HCV patients treated either with PegIFN or an all-oral DAA regimen remain at risk for development of de novo hepatocellular carcinoma.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 31, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Potential markers identified for early detection and prevention of liver cancer
(Frontiers) A new study offers hope of early detection for hepatocellular carcinoma -- the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. The results show a dramatic increase in expression of sugar-burning 'glycolytic' genes in precancerous cirrhotic livers, associated with a significantly higher risk of developing hepatocellular carcinoma. This could lead to a biomarker which identifies those at risk of malignancy, as well as targets for new treatments. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 31, 2018 Category: Biology Source Type: news